Reason: Great business, weak setup. Expected Return is the upside to the analyst price target; full rationale is detailed below.
📌 Is MRK a Buy right now?
According to Ultra Stock Analysis Pro, Merck & Co., Inc. (MRK) is currently rated WAIT (Signal Strength: 0/7). The long-term fundamentals are stable (P/E: 36.5, Revenue Growth: +4.9%), while short-term technicals show a bullish trend (RSI: 67). Consider waiting for support confirmation near $131.14 before adding exposure.
For the latest stock analysis and interactive charts:
📊 Open MRK Analysis ↗
MRK carries a WAIT rating because the underlying business is solid (Investment Quality 63/100), but trend strength is still emerging (ADX 22), relative strength has lagged the S&P 500 over the past quarter and no fresh entry trigger has fired (Signal Strength 0/7). A breakout above $132.80 on improving volume would upgrade the signal toward BUY; a break below $110.37 would mark deeper weakness.
Two independent reads: how good the business is (fundamentals) vs. how good buying it right now is (technicals & timing). A great company is not always a great entry.
MRK: Investment Quality 63/100 vs. Entry Quality 53/100 — weigh business strength against the current setup.
The stock's return minus each benchmark's return. Positive = outperforming = leadership; negative = lagging. Relative strength is one of the most durable signals in quantitative research.
| Benchmark | 1-Mo | 3-Mo | 6-Mo |
|---|---|---|---|
| S&P 500 (SPY) | +14.5% | -6.0% | +15.0% |
| Healthcare (XLV) | +0.5% | -3.3% | +17.9% |
| Pharma (XPH) | -7.9% | -14.9% | +4.3% |
MRK 3-month return: +8.0% · Leadership: LAGGARD — trailing the S&P 500 and its sector
What is driving the view — every factor's signed contribution to one net score. Green adds to the bull case; red detracts.
| Factor | Contribution | Pts |
|---|---|---|
| Valuation Fwd P/E 13.5, PEG 2.8 | +15 | |
| Trend EMA bullish, ADX 22 | +8 | |
| Profitability Margin 14%, ROE 19% | +7 | |
| Momentum RSI 67, MACD bullish | +5 | |
| Revenue Growth +5% YoY | +3 | |
| Sentiment Slightly Bullish | +3 | |
| Earnings Growth +0% YoY | +0 | |
| Volatility ATR 2.6% of price | -1 | |
| Relative Strength -8.1% vs benchmarks (3M) | -8 |
Net Factor Score: +32 — Net bullish. This weighs the broad bull/bear case; the entry signal (Signal Strength) governs timing — a strong factor score can still read WAIT until a setup triggers.
A gradient-boosted model's estimated probability that price closes higher over each horizon (directional estimate, not a guarantee).
● Top 25% in sector ● Middle 50% ● Bottom 25% — each value colored by its rank among 11 Drug Manufacturers - General peers; "med" is the peer median.
Why this rating?
The Ultra Stock Analysis algorithm has assigned a WAIT rating to MRK based on a confluence of 3 distinct factors:
📊 Confidence Interval:
Based on 7+ years of historical data, signals with this specific technical fingerprint have resulted in a positive return 50% of the time across 20 historical trades over a medium-term (months) hold period, with an average return of +2.2% per trade.
📊 How the Signal Strength score works (and why it can read low in an uptrend)
Signal Strength is a tactical entry-timing score, not a trend or fundamentals grade. It only adds points from setups that flag a fresh reason to enter — breakouts, momentum divergences, and oversold/volume/volatility extremes. Trend direction and fundamentals are scored in their own sections above. A setup must reach 3+ points to register as a signal and 5+ for a strong BUY. Individual boxes below can be checked — a stacked EMA trend alone is worth 2 points — without crossing the 3-point bar; when that happens the registered Signal Strength stays at 0/7, meaning no new entry trigger today — not a bearish call.
| Signal | Pts | What it flags | Now |
|---|---|---|---|
| Valid Breakout | 3 | Close breaks above the 20-day high on >1.5× volume | ✗ |
| EMA Trend Alignment | 2 | EMA20 > EMA50 > EMA200 (stacked uptrend) | ✓ |
| RSI Bullish Divergence | 2 | Price firms while RSI was falling — a reversal setup | ✗ |
| MACD Bullish Divergence | 2 | Price firms while MACD was falling — a reversal setup | ✗ |
| Strong Trend (ADX > 25) | 1 | ADX > 25 confirming the stacked EMAs | ✗ |
| High Volume (>1.5×) | 1 | Volume surge confirming the move | ✗ |
| RSI Oversold | 1 | RSI < 30 — stretched to the downside (bounce setup) | ✗ |
| Below Lower Bollinger | 1 | Close below the lower band (mean-reversion setup) | ✗ |
| Volume Accumulation | 1 | Up-volume divergence — quiet accumulation | ✗ |
Points met on the latest bar: 2 → registered Signal Strength 0/7. A setup must reach 3+ points to register as a signal (5+ for a strong BUY); below that it reads 0.
This is why MRK can show a bullish EMA trend and solid fundamentals while Signal Strength reads 0/7: those are already-in-trend and value measures, whereas this score fires only on a new tactical setup (an oversold bounce, a divergence, or a high-volume breakout) — none of which is present on the latest bar.
To assist with risk management, here are the three most probable paths for MRK over the next trading week:
🟢 The Bull Case (Probability: 20%)
If MRK reclaims the $131.14 resistance level (Bollinger Upper), algorithmic targets shift to $131.14. This move would likely be driven by continued sector rotation into Healthcare.
🔴 The Bear Case (Probability: 50%)
Failure to hold the $110.37 support zone (Bollinger Lower) triggers a defensive stop-loss signal. In this scenario, the algorithm projects a slide toward the $106.97 liquidity zone (-17.4% from current price).
🟡 The Base Case (Sideways)
Given the current ADX of 22 (weak trend - consolidation likely), the most likely immediate outcome is consolidation between $110.37 and $131.14 until a volume catalyst occurs.
⚠️ These scenarios are algorithm-generated projections based on technical analysis, not financial advice. Past performance does not guarantee future results.
| TECHNICAL METRICS | VALUE | FUNDAMENTAL METRICS | VALUE |
|---|---|---|---|
| Current Price | $129.56 | Market Cap | $320.0B |
| Past Win Rate (Backtest) | 50.0% (20 trades) | Forward P/E | 13.5x |
| Past Total Return | +18.4% | Analyst Target | $131.11 |
| RSI / Trend Strength | 67 / 22 | Upside to Target | +1.2% |
| MACD Signal | Bullish | Revenue Growth | +4.9% |
| Profit Factor | 1.77 | Institutional Own. | 82.2% |
| Position Entry | 2026-05-26 @ $118.87 | Analyst Ratings | 19 Buy / 10 Hold / 0 Sell |
| Open Position Past P&L | +9.0% |
MAINTAIN POSITION - Current position showing 9.0% unrealized gain. Use intelligent stop loss strategy below.
Both strategies analyzed independently. Conservative uses fixed 2.0x ATR stops. Adaptive adjusts stops based on position profit (tighter as profit grows).
Fixed 2.0x ATR Stop Loss
Entry: $118.87 on 2026-05-26
Confluence: nan
Stop Loss: $122.77
Backtest Results (Since 2018):
Past Win Rate
50%
Past Total Return
+18.4%
Max Drawdown
-11.7%
Avg Trade
+2.2%
Trades
20
Adaptive ATR Stop Loss (1.0-2.75x)
Entry: $118.87 on 2026-05-26
Confluence: nan
Stop Loss: $124.47
Backtest Results (Since 2018):
Past Win Rate
52%
Past Total Return
+23.6%
Max Drawdown
-8.6%
Avg Trade
+2.5%
Trades
21
Current Price
$129.56
Buy Stop Loss
$122.77
Distance: 5%
Conservative 2.0x
Position Stop Loss
$123.62
Distance: 5%
Hybrid 1.75x
ATR 14 Day
$3.39
Volatility
ADX Strength
21.6
Emerging trend
Position up +9% - Adaptive strategy adjusts for momentum
ADX: 20-25 = Emerging trend | 25-50 = Strong trend | 50+ = Very strong
Recent upgrades, downgrades, and price target changes (last 90 days)
| Firm | Action | From → To | Date |
|---|---|---|---|
| CICC | INITIATED | Outperform | Jun 24, 2026 |
| Average Target: | $131.11 | High Target: | $155.00 |
| Current Price: | $129.56 | Low Target: | $100.00 |
| Upside to Average: | +1.2% | Number of Analysts: | 27 |
Based on backtest performance (Win Rate: 50.0% over 20 trades, Avg Return: +2.2%) and analyst consensus (Target: $131.11, +1.2% upside), a MARKET WEIGHT exposure may be considered. Risk/Reward ratio of 0.23:1 (reward to analyst target vs. distance to the stop) suggests unfavorable risk-adjusted returns. Current open position shows +9.0% unrealized gain.
Merck & Co., Inc. operates in the Healthcare sector (Drug Manufacturers - General). Current valuation of 13.5x forward P/E reflects discounted multiples relative to growth prospects. Operating margin of 38.6% shows strong profitability.
Fundamental Outlook: Neutral - Mixed signals with focus on execution and margin improvement
Overall Score: 2.9/10 - Slightly Bullish
Merck (NYSE:MRK) reported positive Phase 3 results for tulisokibart, an anti-TL1A monoclonal antibody in moderate-to-severe ulcerative colitis. The co...
Merck stock is in a buy zone after hitting a new high. Fellow Dow stock JPMorgan Chase and Amphenol are both trading around entry points....
The news sentiment is moderately bullish, showing generally positive coverage with some caution. Market perception appears favorable but not overwhelmingly positive. This neutral-to-positive sentiment suggests steady conditions without extreme optimism.
Comprehensive Technical Data for Quantitative Analysis
| Indicator | Value | Indicator | Value |
|---|---|---|---|
| Close Price | $129.56 | Volume | 7.8M |
| Beta | 0.20 | Avg Volume | 10.4M |
| EMA 20 | $121.87 | EMA 50 | $118.39 |
| EMA 200 | $108.23 | Current Price | $129.56 |
| RSI (14) | 66.65 | MACD | 3.261 |
| MACD Signal | 2.188 | MACD Histogram | 1.072 |
| Trend Strength (ADX) | 21.60 | Volatility (ATR 14) | $3.39 |
| Bollinger Upper | $131.14 | Bollinger Lower | $110.37 |
| Stochastic %K | 86.75 | Stochastic %D | 89.75 |
| VWAP | $128.39 | Bollinger Middle | $120.75 |
| Confluence Score | 0/7 | Trade Signal | NONE |
Comprehensive Fundamental Data for Financial Analysis
| Valuation Metrics | Performance | ||
|---|---|---|---|
| Market Cap | $320.0B | Revenue | $65.8B |
| Forward P/E | 13.5 | Revenue Growth | +4.9% |
| Trailing P/E | 36.5 | Gross Margin | 76.7% |
| Price/Sales | 4.87 | Operating Margin | 38.6% |
| Price/Book | 6.97 | Profit Margin | 13.6% |
| PEG Ratio | 2.76 | ROE | 18.9% |
| Enterprise Value | $363.5B | Free Cash Flow | $14.0B |
| EPS (Forward) | $9.59 | Dividend Yield | 2.62% |
| 52-Week Range | $76.66 - $130.29 | ||
Comprehensive Trading Performance and Position Details
| Entry Date | Entry Price | Past P&L | Entry Stop Loss |
|---|---|---|---|
| 2026-05-26 | $118.87 | +9.00% | $114.62 |
| Entry Date | Exit Date | Entry Price | Exit Price | Return % | Result |
|---|---|---|---|---|---|
| 2022-11-30 | 2022-12-14 | $98.40 | $100.33 | +1.97% | Win |
| 2023-01-27 | 2023-06-07 | $94.78 | $98.37 | +3.78% | Win |
| 2023-10-19 | 2024-02-07 | $92.19 | $117.86 | +27.84% | Win |
| 2024-03-27 | 2024-04-11 | $122.59 | $117.38 | -4.25% | Loss |
| 2024-06-28 | 2024-07-16 | $115.88 | $117.42 | +1.32% | Win |
| 2024-11-15 | 2025-02-07 | $90.75 | $82.90 | -8.65% | Loss |
| 2025-04-16 | 2025-07-25 | $73.25 | $81.97 | +11.90% | Win |
| 2025-10-02 | 2025-10-17 | $87.47 | $82.86 | -5.27% | Loss |
| 2025-11-18 | 2026-01-08 | $94.23 | $109.39 | +16.08% | Win |
| 2026-02-03 | 2026-04-28 | $114.17 | $109.24 | -4.31% | Loss |
Summary: 20 total trades | Strategy: Conservative Stop Loss (Fixed ATR-based)
Disclaimer: This report is for informational and educational purposes only and does not constitute investment advice. Ultra Stock Analysis Pro is not a registered investment advisor; information is impersonal and not tailored to individual circumstances. AI-generated content may contain errors — verify before acting. Past performance is not indicative of future results. Technical analysis based on historical data through 2026-07-02. Fundamental data auto-fetched from Yahoo Finance. Please conduct your own due diligence before making investment decisions.
Report Generated: July 05, 2026 at 01:15 PM
Ultra Stock Analysis Pro - Comprehensive Technical & Fundamental Analysis